• Medicine
  • Published in
    Gan to kagaku ryoho. Cancer…
    1987

[Phase II study of a new nitrosourea derivative, MCNU, in tablet form. Takai Blood Cancer Study Group].

@article{Kobayashi1987PhaseIS,
  title={[Phase II study of a new nitrosourea derivative, MCNU, in tablet form. Takai Blood Cancer Study Group].},
  author={T Kobayashi and Ikuta Tanaka and Shigeru Shirakawa and Yuushi Fujiwara and Yutaka Hirota and Mariko Kobayashi and Ryuzo Ohno and Hirofumi Yamada and Yasuharu Mitomo and Mitsuo Yamamoto},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={1987},
  volume={14 4},
  pages={
          1079-85
        }
}
A phase II study of the oral agent methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU tablet) for myeloproliferative disorders was performed. Fifty-two patients were treated with MCNU tablets and 43 patients were evaluated for clinical effects and 45 for adverse effects. The standard regimen was as follows; oral administration of 50mg (one tablet)/body/day every 4-6 days was considered as one course, and this was repeated at 6-8-week intervals if possible, with… CONTINUE READING